Ryan Heit's Contact Details

Ryan Heit's Company Details

Pacylex is a Canadian oncology company exploiting a new discovery in cancer biology which may explain how some cancers arise from normal cells. The company is leveraging this discovery by developing a first-in-class, oral drug, PCLX-001, to turn on selective lethality, apoptosis, in these cancer cells, while leaving normal cells unharmed. Animal tests show this drug candidate completely eliminates tumors in xenograft models of leukemias and lymphomas. PCLX-001 also kills many solid tumor cancer cell lines and retards tumor growth in models of human lung and breast cancer. Pacylex is part of the initial class at the Merck Accelerator in Edmonton and is on a firm development track consistent with an IND filing in early 2020 for PCLX-001.